• Targeted melanoma therapy: New developments in the treatment of cutaneous melanoma include gene protein-targeted BRAF inhibitors, such as vemurafenib (Zelboraf®), ipilimumab (Yervoy®), and dabrafenib (Tafinlar®), and MEK inhibitors, such as trametinib (Mekinist®). Results are promising and offer less toxic and more effective regimens than standard chemotherapy.
• Molecular diagnosis of melanoma: Previously undefinable lesions can now be defined using array techniques, such as comparative genomic hybridization and fluorescence in situ hybridization, to aid in classification and treatment decisions.
• Biologic treatments for inflammatory disease: Biologic treatments, including adalimumab (Humira®), etanercept (Enbrel®), ustekinumab (Stelara®), and secukinumab (Cosentyx®), are FDA-approved to treat psoriasis, with the achievement of Psoriasis Area and Severity Index scores now approaching 100%. However, the costs of treatment have escalated.
• Rituximab for immunobullous disease: Rituximab, a monoclonal anti-CD20 antibody, can be used in the treatment of immunobullous diseases, effectively turning off antibody production and markedly reducing mortality and morbidity in such conditions as bullous pemphigoid, pemphigus, dermatitis herpetiformis, and linear immunoglobulin A (IgA) disease.
• Dermal fillers and relaxers: With a wide menu of products available, many options are available. Correct placement and choice of filler, as well as patient education, are keys to patient satisfaction.
Top dermatology advances selected by William D. James, MD, Paul R. Gross Professor of Dermatology; Vice-Chairman; Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
For more on advancements in dermal fillers and relaxers, read here.
Medscape © 2015
Cite this: What Do You Consider to Be the Top Medical Advances of the Past 20 Years? - Medscape - May 27, 2015.